Leave Behind Liabilities
Our SAFIRE technology combines the power of AI with high-quality Eurofins Discovery proprietary data to supercharge drug discovery. SAFIRE is a suite of AI models that provide fast and accurate predictions for ADMET favorability and liability. SAFIRE can help reduce overall costs and timelines by more than 30% while also delivering a better molecule to the clinic. Whether you have 10 or 10,000 molecules, let SAFIRE guide the next steps in your drug discovery journey.
Unleash the Power of Precision: Eurofins Proprietary Data Sets Us Apart
The journey begins with the foundation – high-quality data. In the dynamic realm of machine learning and artificial intelligence, data quality stands as the linchpin determining the success or failure of machine learning models. SAFIRE models are trained using the best data in the industry. When provided with high-quality, well-curated, and chemically diverse datasets such as the Eurofins proprietary BioPrint database, AI models can identify subtle patterns and make nuanced predictions empowering optimal decision-making for our clients. At its inception, BioPrint sought to understand what makes certain drug molecules better than unsuccessful candidates. Today the BioPrint database contains over 1 million experimental data points across over 2,500 compounds with little overlap to publicly available databases providing SAFIRE models with a significant competitive advantage over the industry standard.
Use SAFIRE today to elevate your decision-making with insights that you can trust.
To learn more about the science behind SAFIRE, check out our recent publication
The SAFIRE publication provides an in-depth discussion around state-of-the-art AI model development and performance for solubility, Caco-2 permeability, hERG, plasma protein binding, metabolic stability, Caco-2 efflux ratio, and CYP inhibition isoforms 1A2, 2D6, 3A4/3A5, 2C9, 2C19, 2B6, 2C8. All models demonstrate competitive performance at ≥ 75% accuracy and ≥ 0.4 Matthew’s Correlation Coefficient.
BioPrint meets the AI age: development of artificial intelligence-based ADMET models for the drug-discovery platform SAFIRE | Future Medicinal Chemistry (future-science.com)
Ready to try SAFIRE yourself? Getting started is as easy as 1…2…3!
